GS
GSK.US GSK plc
- Market cap
- USD 101B
- P/E
- 17.6x
- P/B
- 4.06x
- ROE
- 26.2%
- Dividend yield
- 3.64%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is GSK.US undervalued?
Graham numberGSK.US trades 78.1% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
GSK plc fundamental analysis
No fundamental analysis for GSK plc yet.
GSK plc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About GSK plc
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, …
Full company profileGSK plc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
GSK plc annual financial statements (GBP; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 27.9B | 30.2B | 30.8B | 33.8B | 24.4B | 24.7B | 29.3B | 30.3B | 31.4B | 32.7B | 33.1B |
| Gross Profit | 18.6B | 19.8B | 20.6B | 21.9B | 16.4B | 16.5B | 19.8B | 21.8B | 22.3B | 23.7B | 24.6B |
| Operating Income | 2.60B | 4.09B | 5.48B | 6.96B | 5.98B | 4.36B | 6.43B | 6.75B | 4.02B | 7.93B | 7.10B |
| EBITDA | 4.43B | 6.18B | 7.35B | 9.43B | 8.07B | 6.49B | 8.56B | 9.15B | 6.67B | 10.4B | 9.09B |
| Net Income | 912M | 1.53B | 3.62B | 4.65B | 5.75B | 4.39B | 15.0B | 4.93B | 2.58B | 5.72B | 4.94B |
| EPS | 0.46 | 0.78 | 1.82 | 2.32 | 2.85 | 2.71 | 7.32 | 2.40 | 1.24 | 2.78 | 2.42 |
| Balance Sheet | |||||||||||
| Total Assets | 59.1B | 56.4B | 58.1B | 106B | 110B | 107B | 60.1B | 75.2B | 59.5B | 61.1B | 72.2B |
| Total Liabilities | 54.1B | 52.9B | 54.4B | 81.3B | 81.5B | 78.2B | 50.1B | 58.9B | 46.4B | 45.2B | 53.7B |
| Shareholders' Equity | 4.96B | 3.49B | 3.78B | 15.1B | 19.9B | 20.4B | 10.6B | 17.0B | 13.7B | 16.4B | 18.9B |
| Cash & Short-term Investments | 4.99B | 3.91B | 3.96B | 6.34B | 8.71B | 5.87B | 7.88B | 6.61B | 3.71B | 3.40B | 2.98B |
| Total Debt | 18.8B | 17.1B | 26.1B | 40.4B | 37.1B | 32.7B | 21.0B | 23.0B | 17.0B | 17.7B | 23.9B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 6.50B | 6.92B | 8.42B | 8.02B | 8.44B | 7.95B | 7.40B | 6.77B | 6.55B | 7.74B | 8.62B |
| Capital Expenditure | 2.35B | 2.20B | 1.80B | 2.16B | 2.24B | 2.93B | 2.26B | 2.34B | 2.98B | 1.35B | 1.53B |
| Free Cash Flow | 4.15B | 4.72B | 6.63B | 5.86B | 6.20B | 5.02B | 5.15B | 4.42B | 3.57B | 6.39B | 7.09B |
| Ratios | |||||||||||
| ROE | 18.4% | 43.9% | 95.8% | 30.7% | 28.8% | 21.5% | 141.1% | 29.0% | 18.8% | 34.9% | 26.2% |
| ROA | 1.5% | 2.7% | 6.2% | 4.4% | 5.2% | 4.1% | 24.9% | 6.6% | 4.3% | 9.4% | 6.8% |
| Net Profit Margin | 3.3% | 5.1% | 11.8% | 13.8% | 23.6% | 17.8% | 51.0% | 16.2% | 8.2% | 17.5% | 14.9% |
| Debt to Equity | 3.79x | 4.90x | 6.89x | 2.67x | 1.86x | 1.61x | 1.98x | 1.35x | 1.24x | 1.08x | 1.26x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
GSK plc dividends
- Dividend yield
- 3.64%
- Forward dividend
- 1.83 USD
- Payout ratio
- 44.9%
- Ex-dividend date
- Nov 13, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | GBP 2.56B | 1.25 | 44.9% |
| 2024 | GBP 2.44B | 1.18 | 94.9% |
| 2023 | GBP 2.25B | 1.09 | 45.6% |
| 2022 | GBP 3.47B | 1.70 | 23.2% |
| 2021 | GBP 4.00B | 2.47 | 91.2% |
| 2020 | GBP 3.98B | 1.97 | 69.2% |
| 2019 | GBP 3.95B | 1.97 | 85.1% |
| 2018 | GBP 3.93B | 1.97 | 108.4% |
| 2017 | GBP 3.91B | 1.98 | 255.0% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1226:1000 on Jul 22, 2022.
Who owns GSK plc
- Insiders 0.18%
- Institutions 16.83%
- Public & others 83.00%
- Shares outstanding 2.00B
- Free float 1.94B
Top funds holding GSK.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Dodge & Cox Stock I | 30.3M | 1.51% | -10.38% | Sep 2026 |
| Vanguard PRIMECAP Inv | 18.2M | 0.91% | +0.21% | Sep 2026 |
| Vanguard Wellington Inv | 8.64M | 0.43% | -10.62% | Sep 2026 |
| Strategic Advisers Fidelity US TtlStk | 8.05M | 0.40% | +0.44% | Sep 2026 |
| Fidelity Series Large Cap Stock | 4.58M | 0.23% | 0.00% | Sep 2026 |
| Fidelity Series Value Discovery | 3.94M | 0.20% | -0.22% | Sep 2026 |
| Vanguard PRIMECAP Core Inv | 3.56M | 0.18% | +0.28% | Sep 2026 |
| Fidelity Growth & Income | 3.44M | 0.17% | 0.00% | Sep 2026 |
| Dodge & Cox Balanced I | 3.09M | 0.15% | -10.27% | Sep 2026 |
| Fidelity Select Pharmaceuticals Port | 2.71M | 0.14% | +5.06% | Sep 2026 |
| Fidelity Equity Dividend Income | 2.70M | 0.13% | 0.00% | Sep 2026 |
| T. Rowe Price International Value Eq | 2.60M | 0.13% | -1.51% | Sep 2026 |
| Vanguard Windsor II Inv | 1.82M | 0.09% | +13.80% | Sep 2026 |
| Fidelity Large Cap Stock | 1.71M | 0.09% | 0.00% | Sep 2026 |
| Bridge Builder Large Cap Value | 1.47M | 0.07% | -3.08% | Oct 2026 |
| Avantis International Equity ETF | 1.45M | 0.07% | 0.00% | Oct 2026 |
| BGF World Healthscience A2 | 1.19M | 0.06% | 0.00% | Jul 2026 |
| Fidelity Enhanced International ETF | 1.14M | 0.06% | 0.00% | Oct 2026 |
| PRIMECAP Odyssey Stock | 1.12M | 0.06% | 0.00% | Sep 2026 |
| Fidelity Advisor Capital Development O | 1.08M | 0.05% | 0.00% | Sep 2026 |
Top institutions holding GSK.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| FMR Inc | 65.0M | 3.24% | -3.99% | Jun 2026 |
| Dodge & Cox | 48.2M | 2.40% | -17.84% | Jun 2026 |
| Fisher Asset Management, LLC | 35.7M | 1.78% | +3.48% | Jun 2026 |
| PRIMECAP Management Company | 25.2M | 1.26% | +0.04% | Sep 2026 |
| Wellington Management Company LLP | 11.4M | 0.57% | -2.74% | Jun 2026 |
| JTC Employer Solutions Trustee Ltd | 8.59M | 0.43% | -4.97% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 7.66M | 0.38% | -30.58% | Jun 2026 |
| Royal Bank of Canada | 7.59M | 0.38% | +1.09% | Jun 2026 |
| T. Rowe Price Associates, Inc. | 6.92M | 0.35% | -5.45% | Jun 2026 |
| The Goldman Sachs Group Inc | 6.37M | 0.32% | -33.56% | Jun 2026 |
| State Street Corp | 5.96M | 0.30% | -0.66% | Jun 2026 |
| Mondrian Investment Partners Ltd | 4.91M | 0.25% | -1.54% | Jun 2026 |
| Acadian Asset Management LLC | 4.55M | 0.23% | -31.62% | Sep 2026 |
| Bank of Montreal | 4.04M | 0.20% | -12.87% | Jun 2026 |
| BMO Capital Markets Corp. | 4.04M | 0.20% | -12.87% | Jun 2026 |
| BlackRock Inc | 3.62M | 0.18% | +1.95% | Jun 2026 |
| Grantham, Mayo, Van Otterloo & Co., LLC | 3.60M | 0.18% | +2.18% | Jun 2026 |
| Hotchkis & Wiley Capital Management LLC | 3.41M | 0.17% | -1.97% | Jun 2026 |
| Equity Investment Corp | 3.27M | 0.16% | +1.51% | Jun 2026 |
| UBS Group AG | 2.81M | 0.14% | +34.64% | Jun 2026 |
GSK plc company profile
- Company name
- GSK plc
- Ticker
- GSK.US
- Exchange
- USA Stocks
- Listed since
- Jul 9, 1986
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 66,841
- Fiscal year end
- December
- Address
- 79 New Oxford Street, London, United Kingdom, WC1A 1DG
- Phone
- 44 20 8047 5000
- Website
- gsk.com
About GSK plc
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It also provides vaccines for Shingles, Meningitis, RSV, Seasonal Influenza, Hepatitis, Diphtheria, Tetanus, Acellular Pertussis, Rotavirus, Pertussis, Polio, Haemophilus, Invasive Diseases, Pneumonia, Acute Otitis Media, Measles, Mumps, Rubella and Chickenpox, and Human Papilloma Virus. Additionally, the company offers general medicines for asthma, COPD, bacterial infection, benign prostatic hyperplasia, allergic rhinitis, and inflammatory skin conditions. It also focuses on the discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. It has a collaboration agreement with CureVac to develop mRNA vaccines for infectious diseases; and strategic research collaboration with Engitix Ltd. to identify and validate novel therapeutic targets driving liver fibrosis regression. The company has a strategic alliance with AN2 Therapeutics, Inc. for the development of new therapies for TB. GSK plc was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. The company was founded in 1715 and is headquartered in London, United Kingdom.
GSK plc management
10- Ms. Julie Belita Brown A.C.A.CFO & Executive Director · born 1962
- Dr. Jesse L. Goodman M.D., M.P.H.Scientific & Medical Expert · born 1951
- Mr. Luke Victor MielsCEO & Director · born 1974
- Ms. Shobie RamakrishnanChief Digital & Technology Officer · born 1971
- Mr. Tony WoodChief Scientific Officer and Head of R&D
- Mr. Jeff McLaughlinVP of Investor Relations & Interim Head of Investor Relations
- Mr. James FordSenior VP and Group General Counsel of Legal & Compliance
- Mr. David Simon Redfern BSc (Hons), CAPresident of Corporate Development · born 1966
- Ms. Roanne ParryChief People Officer · born 1974
- Mr. Philip C. ThomsonPresident of Global Affairs